INTRODUCTION: Homozygosity for a 5-leucine repeat (5L-5L) in the carnosinase gene (CNDP1) has been associated with a reduced prevalence of diabetic nephropathy in cross-sectional studies in patients with type 2 diabetes, particularly in women. Prospective studies on mortality are not available. This study investigated whether 5L-5L was associated with mortality and progression of renal function loss and to what extent this effect is modified by sex. METHODS: In a prospective cohort of patients with type 2 diabetes, a Cox proportional hazard model was used to compare 5L-5L with other genotypes regarding (cardiovascular) mortality. Renal function slopes were obtained by within-individual linear regression of the estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) equation, and were compared between 5L-5L and other genotypes. RESULTS: 871 patients were included (38% with 5L-5L). After 9.5 years of follow-up, hazards ratios (HR) for all-cause and cardiovascular mortality in 5L-5L versus other genotypes were 1.09 [95% confidence interval (CI) 0.88-1.36] and 1.12 (95% CI 0.79-1.58), respectively. There was a significant interaction between CNDP1 and sex for the association with cardiovascular mortality (p = 0.01), not for all-cause mortality (p = 0.32). Adjusted HR in 5L-5L for cardiovascular mortality was 0.69 (95% CI 0.39-1.23) in men and 1.77 (95% CI 1.12-2.81) in women. The slopes of eGFR-MDRD did not significantly differ between 5L-5L and other genotypes. CONCLUSIONS: The association between CNDP1 and cardiovascular mortality was sex-specific, with a higher risk in women with 5L-5L genotype. CNDP1 was not associated with all-cause mortality or change in eGFR.
INTRODUCTION: Homozygosity for a 5-leucine repeat (5L-5L) in the carnosinase gene (CNDP1) has been associated with a reduced prevalence of diabetic nephropathy in cross-sectional studies in patients with type 2 diabetes, particularly in women. Prospective studies on mortality are not available. This study investigated whether 5L-5L was associated with mortality and progression of renal function loss and to what extent this effect is modified by sex. METHODS: In a prospective cohort of patients with type 2 diabetes, a Cox proportional hazard model was used to compare 5L-5L with other genotypes regarding (cardiovascular) mortality. Renal function slopes were obtained by within-individual linear regression of the estimated glomerular filtration rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) equation, and were compared between 5L-5L and other genotypes. RESULTS: 871 patients were included (38% with 5L-5L). After 9.5 years of follow-up, hazards ratios (HR) for all-cause and cardiovascular mortality in 5L-5L versus other genotypes were 1.09 [95% confidence interval (CI) 0.88-1.36] and 1.12 (95% CI 0.79-1.58), respectively. There was a significant interaction between CNDP1 and sex for the association with cardiovascular mortality (p = 0.01), not for all-cause mortality (p = 0.32). Adjusted HR in 5L-5L for cardiovascular mortality was 0.69 (95% CI 0.39-1.23) in men and 1.77 (95% CI 1.12-2.81) in women. The slopes of eGFR-MDRD did not significantly differ between 5L-5L and other genotypes. CONCLUSIONS: The association between CNDP1 and cardiovascular mortality was sex-specific, with a higher risk in women with 5L-5L genotype. CNDP1 was not associated with all-cause mortality or change in eGFR.
Authors: Bart Janssen; Daniela Hohenadel; Paul Brinkkoetter; Verena Peters; Nina Rind; Christine Fischer; Ivan Rychlik; Marie Cerna; Marianna Romzova; Emile de Heer; Hans Baelde; Stephan J L Bakker; Mahmoud Zirie; Eric Rondeau; Peter Mathieson; Moin A Saleem; Jochen Meyer; Hannes Köppel; Sibylle Sauerhoefer; Claus R Bartram; Peter Nawroth; Hans-Peter Hammes; Benito A Yard; Johannes Zschocke; Fokko J van der Woude Journal: Diabetes Date: 2005-08 Impact factor: 9.461
Authors: Irfan Vardarli; Leslie J Baier; Robert L Hanson; Imren Akkoyun; Christine Fischer; Peter Rohmeiss; Ali Basci; Claus R Bartram; Fokko J Van Der Woude; Bart Janssen Journal: Kidney Int Date: 2002-12 Impact factor: 10.612
Authors: Antien L Mooyaart; Ana Zutinic; Stephan J L Bakker; Diana C Grootendorst; Nanne Kleefstra; Irene G M van Valkengoed; Stefan Böhringer; Henk J G Bilo; Friedo W Dekker; Jan Anthonie Bruijn; Gerjan Navis; Bart Janssen; Hans J Baelde; Emile De Heer Journal: Diabetes Date: 2010-03-23 Impact factor: 9.461
Authors: Sudha K Iyengar; Hanna E Abboud; Katrina A B Goddard; Mohammed F Saad; Sharon G Adler; Nedal H Arar; Donald W Bowden; Ravi Duggirala; Robert C Elston; Robert L Hanson; Eli Ipp; W H Linda Kao; Paul L Kimmel; Michael J Klag; William C Knowler; Lucy A Meoni; Robert G Nelson; Susanne B Nicholas; Madeleine V Pahl; Rulan S Parekh; Shannon R E Quade; Stephen S Rich; Jerome I Rotter; Marina Scavini; Jeffrey R Schelling; John R Sedor; Ashwini R Sehgal; Vallabh O Shah; Michael W Smith; Kent D Taylor; Cheryl A Winkler; Philip G Zager; Barry I Freedman Journal: Diabetes Date: 2007-03-15 Impact factor: 9.461
Authors: Eva Riedl; Hannes Koeppel; Paul Brinkkoetter; Paula Sternik; Herbert Steinbeisser; Sibylle Sauerhoefer; Bart Janssen; Fokko J van der Woude; Benito A Yard Journal: Diabetes Date: 2007-06-29 Impact factor: 9.461
Authors: Krzysztof Wanic; Grzegorz Placha; Jonathon Dunn; Adam Smiles; James H Warram; Andrzej S Krolewski Journal: Diabetes Date: 2008-09 Impact factor: 9.461
Authors: Kunihiro Matsushita; Bakhtawar K Mahmoodi; Mark Woodward; Jonathan R Emberson; Tazeen H Jafar; Sun Ha Jee; Kevan R Polkinghorne; Anoop Shankar; David H Smith; Marcello Tonelli; David G Warnock; Chi-Pang Wen; Josef Coresh; Ron T Gansevoort; Brenda R Hemmelgarn; Andrew S Levey Journal: JAMA Date: 2012-05-09 Impact factor: 56.272
Authors: Thomas Albrecht; Shiqi Zhang; Jana D Braun; Li Xia; Angelica Rodriquez; Jiedong Qiu; Verena Peters; Claus P Schmitt; Jacob van den Born; Stephan J L Bakker; Alexander Lammert; Hannes Köppel; Peter Schnuelle; Bernhard K Krämer; Benito A Yard; Sibylle J Hauske Journal: J Diabetes Res Date: 2017-05-03 Impact factor: 4.011
Authors: Jiedong Qiu; Benito A Yard; Bernhard K Krämer; Harry van Goor; Peter van Dijk; Aimo Kannt Journal: Front Pharmacol Date: 2022-07-08 Impact factor: 5.988